“Intrahepatic Cholangiocarcinoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Intrahepatic Cholangiocarcinoma Market.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Intrahepatic Cholangiocarcinoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Intrahepatic Cholangiocarcinoma and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Intrahepatic Cholangiocarcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NA
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Learn How the Ongoing Clinical & Commercial Activities will Affect the Intrahepatic Cholangiocarcinoma Therapeutic Segment @
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight
Intrahepatic Cholangiocarcinoma Therapeutics Landscape
Currently, the treatment options for early-stage Intrahepatic ICCA majorly include surgery with adjuvant chemotherapy and chemoradiation therapy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high. Radiation therapy uses high-energy rays or particles to destroy cancer cells. The two main types of radiation therapy are external beam radiation therapy (EBRT) and brachytherapy, and EBRT is the most common form of radiation for bile duct cancer.
To improve the treatment scenario, globally, several major pharma and biotech giants are developing therapies for Intrahepatic Cholangiocarcinoma. Currently, Basilea Pharmaceutica is leading the therapeutics market with its Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Intrahepatic Cholangiocarcinoma Therapeutics Market Include:
-
Basilea Pharmaceutica
-
Virogin Biotech Ltd
-
TriSalus Life Sciences
-
Forma Therapeutics, Inc
-
Kinnate Biopharma
-
Relay Therapeutics
-
ABL Bio
-
Hutchison MediPharma
-
Sirnaomics
-
Jiangsu Hengrui Medicine
And Many Others
Intrahepatic Cholangiocarcinoma Drugs Covered in the Report Include:
-
Derazantinib: Basilea Pharmaceutica
-
Durvalumab: AstraZeneca
-
SD 101: TriSalus Life Sciences
-
FT-2102: Forma Therapeutics, Inc.
-
KIN-3248: Kinnate Biopharma
-
RLY-4008: Relay Therapeutics
-
VG161: Virogin Biotech Ltd
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns
4. Intrahepatic Cholangiocarcinoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Intrahepatic Cholangiocarcinoma Late Stage Products (Phase-III)
7. Intrahepatic Cholangiocarcinoma Mid-Stage Products (Phase-II)
8. Intrahepatic Cholangiocarcinoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Intrahepatic Cholangiocarcinoma Discontinued Products
13. Intrahepatic Cholangiocarcinoma Product Profiles
14. Key Companies in the Intrahepatic Cholangiocarcinoma Market
15. Key Products in the Intrahepatic Cholangiocarcinoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Intrahepatic Cholangiocarcinoma Unmet Needs
18. Intrahepatic Cholangiocarcinoma Future Perspectives
19. Intrahepatic Cholangiocarcinoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight
Other Trending Healthcare Reports By DelveInsight
Intrahepatic Cholangiocarcinoma Market Outlook
“Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Intrahepatic Cholangiocarcinoma, historical and forecasted epidemiology as well as the Intrahepatic Cholangiocarcinoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/